August 3, 2021
Vaccine candidate targets vulnerabilities common across many HIV-1 variants.
Features
June 18, 2021
A Q&A with Dr. Gagandeep Kang, professor of microbiology at the Wellcome Trust Research Laboratory, held on May 12, 2021, and co-organized by IAVI...
A commentary by Mark Feinberg, M.D., Ph.D., IAVI president and CEO
IAVI’s Dr. Jayanta Bhattacharya, of the Translational Health Science and Technology Institute, India, is interviewed by DBT/Wellcome Trust India All...
May 21, 2021
IAVI remembers Dr. Deepak Gaur, Deputy Country Director, India, and extends our deepest sympathies to his family.
May 19, 2021
This HIV Vaccine Awareness Day, we join the call for women to be at the center of the HIV response to lead their own solutions.
Scientists and community liaisons highlight the importance of collaboration in achieving an affordable, globally accessible HIV vaccine.
April 10, 2021
A spate of news coverage on the results of the Phase I IAVI G001 HIV vaccine clinical trial reflects current public interest in vaccine development ...
April 2, 2021
IAVI recognizes the Government of India for their unwavering support of the development of safe, effective, accessible, preventive HIV vaccines and bi...
March 29, 2021
Failure to meet commitments for TB research is not inevitable; the global COVID-19 response may show us the way.
IAVI CEO Mark Feinberg charts future HIV-1 vaccine development efforts in NEJM.
Show More
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
